Bausch + Lomb Will Release First-Quarter 2025 Financial Results on April 30
Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its first-quarter financial results on Wednesday, April 30, 2025. Bausch + Lomb will host a conference call and live webcast at 8 a.m. ET to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch + Lomb website prior to the start of the call.
Bausch + Lomb is dedicated to protecting and enhancing the gift of sight for millions of people around the world ? from birth through every phase of life. Its comprehensive portfolio of approximately 400 products includes contact lenses, lens care products, eye care products, ophthalmic pharmaceuticals, over-the-counter products and ophthalmic surgical devices and instruments. Founded in 1853, Bausch + Lomb has a significant global research and development, manufacturing and commercial footprint with approximately 13,500 employees and a presence in approximately 100 countries. Bausch + Lomb is headquartered in Vaughan, Ontario, with corporate offices in Bridgewater, New Jersey. For more information, visit www.bausch.com and connect with us on X, LinkedIn, Facebook and Instagram.
Richter Inc., in its capacity as court-appointed monitor (in such capacity, the "Monitor") of Synaptive Medical Inc., ("Synaptive" or "Company") pursuant to the Companies' Creditors Arrangement Act, R.S.C. 1985, c. C-36, as amended (the "CCAA"), is...
Fenplast is honored to renew its support as the official co-presenter of the 2025 Leucan Ski Challenge, marking the 20th anniversary of this flagship event benefiting children with cancer and their families. Fenplast reaffirms its commitment to a...
On March 20, Zylox-Tonbridge Medical Technology Co., Ltd. (Stock Code: 2190.HK, hereinafter referred to as "Zylox-Tonbridge" or the "Company") released its 2024 annual results. In 2024, the Company reported revenue of USD 109.4 million, a...
Shanghai Junshi Biosciences Co., Ltd ("Junshi Biosciences," HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced its financial...
Product: Hummus
Issue:Food - Allergen - Peanut
Distribution:AlbertaBritish ColumbiaPossibly other provinces and territories
See the affected products and product photos for this recall
SOURCE Canadian Food Inspection Agency (CFIA)
WELL Health Technologies Corp. ("WELL" or the "Company"), a digital healthcare company focused on positively impacting health outcomes by leveraging technology to empower healthcare practitioners and their patients globally, announces that it will...